SK Bioscience start to deliver Novavax COVID-19 vaccine

The vaccine is an updated protein-based non-mRNA COVID-19 vaccine against XBB.1.5, XBB.1.16, and XBB.2.3 variants

SK Bioscience start to deliver Novavax COVID-19 vaccine
Ji-Hyun Lee 1
2023-12-12 14:29:18 bluesky@hankyung.com
Bio & Pharma

South Korea's SK Bioscience Co. announced on Tuesday that it started to deliver the Novavax COVID-19 vaccine against XBB.1.5 variant.

According to Novavax, this vaccine is the only one approved as an updated protein-based non-mRNA COVID-19 vaccine against XBB.1.5, XBB.1.16, and XBB.2.3 variants.

SK Bioscience received a license for Novavax COVID-19 vaccine for emergency use authorization from the Ministry of Food and Drug Safety on Nov. 29. for people aged 12 and older.

In August, SK Bioscience extended its licensing agreement with Novavax, securing exclusive rights for the supply and production of this vaccine in South Korea and non-exclusive distribution rights in Thailand and Vietnam.

Write to Ji-Hyun Lee at bluesky@hankyung.com
#SK Bioscience #Novavax #COVID-19 vaccine #XBB.1.5 variant #protein-based non-mRNA

SK Bioscience applies Phase 3 trials in US for pneumococcal vaccine

SK Bioscience applies Phase 3 trials in US for pneumococcal vaccine

South Korea's SK Bioscience Co. announced on Monday that it submitted the Investigational New Drug (IND) application for the Phase 3 clinical trial plan of the 21-valent pneumococcal protein conjugate vaccine candidate GBP410, developed in collaboration with Sanofi SA, to the US Food and Drug

SK Bioscience resumes output of flu vaccine after two years

SK Bioscience resumes output of flu vaccine after two years

SK Bioscience Co., the drug-making unit of South Korea’s SK Group, on Wednesday shipped SKYCellflu, its vaccine for the common flu, for the first time in two years.By early next year, the domestic market will get about five million doses of SKYCellflu, the world's first cell culture-base

SK Bioscience buys 6.5 million Novavax shares for $83.4 million

SK Bioscience buys 6.5 million Novavax shares for $83.4 million

SK Bioscience CEO Ahn Jae-yong (left) and Novavax CEO John C. Jacobs pose for a photo after signing a strategic partnership agreement SK Bioscience Co., the drug-making unit of South Korea’s SK Group, said on Wednesday it has signed a deal to buy 6.5 million shares in US vaccine maker Nov

SK Bioscience’s COVID-19 vaccine gets approval in UK

SK Bioscience’s COVID-19 vaccine gets approval in UK

SK Bioscience Co., the drug-making unit of South Korea’s SK Group, said on Monday that its domestic COVID-19 vaccine, SKYCovione, has received official marketing approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).The approval allows SKYCovione to be us
(* comment hide *}